The JN.1 Novavax vaccine is an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines that were rolled out in October ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep your expectations in check.

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control and ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Pfizer (PFE) announced it does not anticipate significant changes to U.S. vaccine policy under the incoming Trump administration, despite vaccine skeptic Robert F. Kennedy Jr.’s nomination to lead the ...

If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite ...

The vaccine needs to be stored at around -70 degrees Celsius. Early data revealed Monday that Pfizer's COVID-19 vaccine candidate could be up to 90% effective. The company still needs to submit its ...

The Food and Drug Administration has approved approve the first RSV vaccine that can be given during pregnancy to protect newborn babies. The Food and Drug Administration has approved a vaccine ...